Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioXcel Therapeutics, Inc. - Common Stock (NQ:BTAI)

1.630 -0.190 (-10.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioXcel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Expert Ratings for BioXcel Therapeutics
Via Benzinga
Why Beyond Air Shares Are Trading Lower By Around 37%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Beyond Air, Inc. (NASDAQ: XAIR) dipped during Tuesday’s session following weak quarterly results. 
Via Benzinga
Why Is Dementia Focused BioXcel Therapeutics Stock Trading Lower Today?
BioXcel Therapeutics Inc (NASDAQ: BTAI) announced alignment with the FDA's recommendation for a Phase 3 trial in the TRANQUILITY program of BXCL501 for acute treatment of agitation associated  
Via Benzinga
Recap: BioXcel Therapeutics Q3 Earnings
Via Benzinga
Earnings Outlook For BioXcel Therapeutics
Via Benzinga
Where BioXcel Therapeutics Stands With Analysts
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
BioXcel Therapeutics Reveals Survival Data From Prostate Cancer Combo Therapy Trial
BioXcel Therapeutics Inc (NASDAQ: BTAI) announced overall survival (OS) data from its Phase 2 trial of BXCL701 in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in patients wi 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Dow Falls Over 100 Points; Alphabet Shares Tumble After Q3 Results
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Wednesday. The Dow traded down 0.35% to 33,025.71 while the NASDAQ fell 2.45% to 12,817.76.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Owens Corning Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with DLQ. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
BioXcel Therapeutics Inc. (NASDAQ: BTAI) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Shell Layoffs 2023: What to Know About the Latest SHEL Job Cuts
Shell layoffs are on the horizon as the petrol company prepares to cut 200 jobs in 2024 with another 130 jobs under review. 
Via InvestorPlace
Topics Energy Workforce
Exposures Fossil Fuels Layoff
EVGO Stock Slips as TD Cowen Downgrades EVgo
EVgo stock is taking a beating on Wednesday as investors in the EV charging company deal with a downgrade and price cut. 
Via InvestorPlace
Nasdaq Down 1.5%; Microsoft Posts Upbeat Results
U.S. stocks traded lower this morning, with the Nasdaq Composite falling 1.5% on Wednesday. Following the market opening Wednesday, the Dow traded down 0.26% to 33,053.68 while the NASDAQ fell 1.50% to... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is BioXcel Therapeutics (BTAI) Stock Up 42% Today?
BioXcel Therapeutics stock is rising on Wednesday as investors in BTAI stock react to results from an audit on a clinical trial. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
BIOXCEL ALERT: Bragar Eagel & Squire, P.C. is Investigating BioXcel Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Schizophrenia Player BioXcel's Drug Faces Funding Headwinds, Analyst Downgrades Stock
Truist downgraded BioXcel Therapeutics Inc (NASDAQ: BTAI) from Buy to Hold, citing significant near-term funding and  
Via Benzinga
Why Shares of BioXcel Therapeutics Fell This Week
The company's co-founder is leaving, and layoffs are coming. 
Via The Motley Fool
Topics Workforce
Exposures Layoff
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023
Via Benzinga
NASDAQ: BTAI Investor Alert: Deadline on September 5, 2023 in Lawsuit Against BioXcel Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 09/05/2023 -- The Shareholders Foundation announced that a deadline is coming up on September 5, 2023 in the lawsuit filed for certain investors of BioXcel Therapeutics,... 
Via SBWire
Topics Lawsuit
Exposures Financial Legal
BTAI DEADLINE TOMORROW: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important September 5 Deadline in Securities Class Action – BTAI
From The Rosen Law Firm, P.A.
Via Business Wire
BTAI DEADLINE ALERT: ROSEN, A LONGSTANDING LAW FIRM, Encourages BioXcel Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important September 5 Deadline in Securities Class Action - BTAI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
BIOXCEL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioXcel Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
BIOXCEL 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioXcel Therapeutics, Inc. - BTAI
From Kahn Swick & Foti, LLC
Via Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioXcel Therapeutics, Inc. (BTAI)
From The Law Offices of Frank R. Cruz
Via Business Wire
4-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
Via ACCESSWIRE
BIOXCEL THERAPEUTICS, INC. (NASDAQ: BTAI) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioXcel Therapeutics, Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.